Evidence map›Paper›PMID 41620708›Full record

ArticleWorld journal of surgical oncology2026

Survival prognosis and influencing factors in elderly patients with stage I-III breast cancer.

Yaling Zeng, Purong Zhang, Yuying Wang, Xihui Tu, Di Lu, Huixi Zhong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yaling ZengSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, 611731, China.
Purong ZhangDepartment of Breast, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Center, Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China, Chengdu, Sichuan, China. zprrong123321@163.com.
Yuying WangDepartment of Health Management Center, Qionglai Medical Center Hospital, Qionglai, Sichuan Province, China. jyawyy202@163.com.
Xihui TuNorth Sichuan Medical College, Nanchong, Sichuan Province, China.
Di LuSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, 611731, China.
Huixi ZhongSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, 611731, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo analyse the survival prognosis of elderly patients with stage I-III breast cancer and to explore the related clinicopathological influencing factors.

methodsRetrospective collection of clinicopathological data from elderly breast cancer patients (aged ≥ 65 years) admitted to Sichuan Cancer Hospital between October 2014 and December 2022. Survival curves were generated using the Kaplan–Meier method and comparisons were made using the log-rank test. Univariate and multivariate Cox proportional hazards regression analyses were employed to identify factors independently associated with five-year event-free survival (EFS).

resultsA total of 319 elderly patients with stage I-III breast cancer were included, with a 5-year overall EFS rate of 82.0%. Univariate analysis revealed significant associations between 5-year EFS and age, histological grade, estrogen receptor (ER) status, progesterone receptor (PR) status, Ki-67 level, tumour size (T stage), lymph node status (N stage), and the administration of endocrine therapy (all P < 0.05). Multivariate analysis revealed that age, PR status, T stage, N stage, and Ki-67 level were independent prognostic factors for 5-year EFS.

conclusionsThe results of this study suggest that age, PR status, the Ki-67 index, tumour size, and lymph node metastasis can serve as independent predictors of the 5-year EFS rate in elderly patients with stage I-III breast cancer. Specifically, younger age (≤ 68 years), PR positivity, Ki-67 < 30%, and early T (T1-T2) and N (N0) stages are associated with a more favourable prognosis.

Indexed as

Breast NeoplasmsAgedAged, 80 and overBiomarkers, TumorFemaleFollow-Up StudiesHumansLymphatic MetastasisNeoplasm StagingPrognosisReceptors, EstrogenReceptors, ProgesteroneRetrospective StudiesSurvival RateBiomarkers, TumorReceptors, EstrogenReceptors, ProgesteroneElderly breast cancer patientsEndocrine therapyEvent-free survivalSurvival prognosis

Identifiers

PMID41620708
PMCPMC12933927

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.